| 2.21 0.09 (4.25%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.7 | 1-year : | 2.94 |
| Resists | First : | 2.31 | Second : | 2.52 |
| Pivot price | 2.23  |
|||
| Supports | First : | 1.98 | Second : | 1.64 |
| MAs | MA(5) : | 2.14 |
MA(20) : | 2.25 |
| MA(100) : | 2.23 |
MA(250) : | 1.27 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.8 |
D(3) : | 27.3 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 3.03 | Low : | 0.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IPSC ] has closed above bottom band by 44.9%. Bollinger Bands are 44.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.23 - 2.24 | 2.24 - 2.25 |
| Low: | 2.05 - 2.07 | 2.07 - 2.08 |
| Close: | 2.19 - 2.21 | 2.21 - 2.23 |
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Tue, 09 Jun 2026
Century Therapeutics (IPSC) executive logs small automatic share sale for taxes - Stock Titan
Tue, 09 Jun 2026
Century Therapeutics (IPSC) SVP’s automatic 249-share sale covers RSU tax withholding - Stock Titan
Tue, 09 Jun 2026
Century Therapeutics (NASDAQ: IPSC) CEO has 463 shares withheld for RSU taxes - Stock Titan
Mon, 08 Jun 2026
Century Therapeutics presents preclinical data on diabetes therapy By Investing.com - Investing.com South Africa
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 180 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 12 (%) |
| Held by Institutions | 76.9 (%) |
| Shares Short | 12,210 (K) |
| Shares Short P.Month | 10,960 (K) |
| EPS | -1.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.82 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.3 % |
| Return on Equity (ttm) | -42.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.48 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -95 (M) |
| Levered Free Cash Flow | -54 (M) |
| PE Ratio | -1.94 |
| PEG Ratio | 0 |
| Price to Book value | 1.21 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|